<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320788</url>
  </required_header>
  <id_info>
    <org_study_id>VGFT-OD-0508</org_study_id>
    <nct_id>NCT00320788</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of intravitreally administered VEGF Trap in patients with wet
      AMD.

      The purpose of this trial is to assess the ocular and systemic safety and tolerability of
      repeated intravitreal doses of VEGF Trap in patients with subfoveal choroidal
      neovascularization (CNV) due to AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double masked, prospective, randomized study in which five groups of approximately
      30 patients meeting the eligibility criteria will be randomly assigned in a balanced ratio to
      receive a series of intravitreal (IVT) injections of VEGF Trap into the study eye at 4- or 12
      -week intervals over a 12-week period.

      After Week 12, patients will be evaluated every 4 weeks. Patients will remain on study or may
      be eligible to enter a long-term extension study, in which they will continue to receive VEGF
      Trap.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change of CR/LT From Baseline at Week 12</measure>
    <time_frame>Baseline and at Week 12</time_frame>
    <description>CR/LT measured in micrometers (µm); lower individual values represent better outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change of CR/LT From Baseline at Week 12</measure>
    <time_frame>Baseline and at Week 12</time_frame>
    <description>CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12</measure>
    <time_frame>Baseline and at week 12</time_frame>
    <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12</measure>
    <time_frame>At Week 12</time_frame>
    <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aflibercept injection (VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12</description>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4</arm_group_label>
    <other_name>VEGF Trap-Eye</other_name>
    <other_name>BAY86-5321</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aflibercept injection (VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.</description>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12</arm_group_label>
    <other_name>VEGF Trap-Eye</other_name>
    <other_name>BAY86-5321</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aflibercept injection (VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12</description>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4</arm_group_label>
    <other_name>VEGF Trap-Eye</other_name>
    <other_name>BAY86-5321</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aflibercept injection (VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.</description>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12</arm_group_label>
    <other_name>VEGF Trap-Eye</other_name>
    <other_name>BAY86-5321</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aflibercept injection (VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.</description>
    <arm_group_label>aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12</arm_group_label>
    <other_name>VEGF Trap-Eye</other_name>
    <other_name>BAY86-5321</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subfoveal CNV secondary to AMD.

          -  Central retinal (including lesion) thickness ≥ 300 µm as measured by Optical Coherence
             Tomography (OCT).

          -  Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity of
             73 letters to 34 letters.

        Exclusion Criteria:

          -  History of any vitreous hemorrhage within 4 weeks prior to Day 1.

          -  Aphakia.

          -  Significant subfoveal atrophy or scarring.

          -  Prior treatment with the following in the study eye:

               -  Subfoveal thermal laser therapy.

               -  Submacular surgery or other surgical intervention for the treatment of AMD.

               -  Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1.

               -  Photodynamic therapy (PDT) within 12 weeks prior to Visit 2 (Day 1).

               -  Pegaptanib sodium (Macugen) within 8 weeks of Visit 2 (Day 1).

               -  Juxtascleral steroids or anecortave acetate within 24 weeks (6 months) prior to
                  Visit 2 (Day 1).

               -  Intravitreal administration of triamcinolone acetonide or other steroids within
                  24 weeks prior to Visit 2 (Day 1), unless no visible residue of drug substance
                  can be seen in the vitreous cavity using indirect ophthalmoscopy.

               -  Prior systemic or intravitreal treatment with VEGF Trap, ranibizumab (Lucentis)
                  or bevacizumab (Avastin).

          -  Presence of any other condition or laboratory abnormality, which, in the opinion of
             the Investigator, would interfere with the assessment of disease status/progression or
             jeopardize the patient's appropriate participation in this Phase II study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associated Retina Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Centers, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Retina Consultants PC</name>
      <address>
        <city>West Springfield</city>
        <state>Massachusetts</state>
        <zip>10189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose &amp; Throat Asssociates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean A. McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Northwest PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Diagnostic and Treatment Assoc., LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates, P.C.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Consultants Scurlock Tower Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthamology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21640257</url>
    <description>Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21640258</url>
    <description>The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>December 16, 2011</results_first_submitted>
  <results_first_submitted_qc>January 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2012</results_first_posted>
  <disposition_first_submitted>November 30, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 2, 2010</disposition_first_posted>
  <last_update_submitted>January 27, 2012</last_update_submitted>
  <last_update_submitted_qc>January 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neovascular Age-Related Macular Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 29 study sites in the United States. Recruitment period: May 2006 to April 2007.</recruitment_details>
      <pre_assignment_details>A total of 301 participants were screened; 159 participants were randomized; 157 participants were included in both the Safety Analysis Set (SAF) and the Full Analysis Set (FAS) as all received study treatment, had baseline assessments and at least 1 post-baseline assessment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4</title>
          <description>Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12.</description>
        </group>
        <group group_id="P2">
          <title>Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12</title>
          <description>Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.</description>
        </group>
        <group group_id="P3">
          <title>Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4</title>
          <description>Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12.</description>
        </group>
        <group group_id="P4">
          <title>Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12</title>
          <description>Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.</description>
        </group>
        <group group_id="P5">
          <title>Aflibercept Injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12</title>
          <description>Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="32">Participants Randomized</participants>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment (SAF)</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="31">One participant in this group did not receive treatment and was not included in the SAF and FAS</participants>
                <participants group_id="P4" count="31">One participant in this group did not receive treatment and was not included in the SAF and FAS</participants>
                <participants group_id="P5" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by the Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aflibercept Injection 0.5mg q4</title>
          <description>Participants received 0.5 mg of aflibercept injection at 4 week intervals through Week 12.</description>
        </group>
        <group group_id="B2">
          <title>Aflibercept Injection 0.5mg q12</title>
          <description>Participants received 0.5 mg of aflibercept injection at 12 week intervals through Week 12.</description>
        </group>
        <group group_id="B3">
          <title>Aflibercept Injection 2.0mg q4</title>
          <description>Participants received 2.0 mg of aflibercept injection at 4 week intervals through Week 12.</description>
        </group>
        <group group_id="B4">
          <title>Aflibercept Injection 2.0mg q12</title>
          <description>Participants received 2.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
        </group>
        <group group_id="B5">
          <title>Aflibercept Injection 4.0mg q12</title>
          <description>Participants received 4.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="31"/>
            <count group_id="B6" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.6" spread="7.56" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="78.5" spread="10.12" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="74.9" spread="7.63" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="79.6" spread="8.91" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="78.3" spread="5.97" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="78.2" spread="8.25" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="25" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="20" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="16" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="20" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="15" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="2" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="31" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="29" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="30" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="31" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="32" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="30" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="31" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="31" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Retinal/Lesion Thickness (CR/LT)</title>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="442.2" spread="109.81" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="442.6" spread="136.60" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="453.3" spread="143.93" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="447.0" spread="119.11" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="497.5" spread="191.17" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="456.4" spread="142.41" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best Corrected Visual Acuity (BCVA)</title>
          <description>BCVA as Measured by 4 Meter Early Treatment Diabetic Retinopathy Study (ETDRS)eye charts/measures</description>
          <units>letters read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="13.77" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="55.6" spread="11.75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="57.9" spread="12.02" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B4" value="57.2" spread="10.47" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B5" value="53.0" spread="14.52" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B6" value="55.5" spread="12.57" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change of CR/LT From Baseline at Week 12</title>
        <description>CR/LT measured in micrometers (µm); lower individual values represent better outcomes.</description>
        <time_frame>Baseline and at Week 12</time_frame>
        <population>Full Analysis Set (FAS) used for analysis, Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection 0.5mg q4</title>
            <description>Participants received 0.5 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection 0.5mg q12</title>
            <description>Participants received 0.5 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection 2.0mg q4</title>
            <description>Participants received 2.0 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection 2.0mg q12</title>
            <description>Participants received 2.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O5">
            <title>Aflibercept Injection 4.0mg q12</title>
            <description>Participants received 4.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of CR/LT From Baseline at Week 12</title>
          <description>CR/LT measured in micrometers (µm); lower individual values represent better outcomes.</description>
          <population>Full Analysis Set (FAS) used for analysis, Last Observation Carried Forward (LOCF)</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-153.5" spread="113.30" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="-75.6" spread="110.64" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="-169.2" spread="138.46" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="-56.3" spread="133.05" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="-139.8" spread="228.59" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="-118.8" spread="155.31" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change of CR/LT From Baseline at Week 12</title>
        <description>CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome</description>
        <time_frame>Baseline and at Week 12</time_frame>
        <population>FAS used for analysis, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection 0.5mg q4</title>
            <description>Participants received 0.5mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection 0.5mg q12</title>
            <description>Participants received 0.5mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection 2.0mg q4</title>
            <description>Participants received 2.0mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection 2.0mg q12</title>
            <description>Participants received 2.0mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O5">
            <title>Aflibercept Injection 4.0mg q12</title>
            <description>Participants received 4.0mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change of CR/LT From Baseline at Week 12</title>
          <description>CR/LT measured in micrometers (µm); a more negative percentage represents a better outcome</description>
          <population>FAS used for analysis, LOCF</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.4" spread="18.92" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="-15.2" spread="22.52" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="-33.2" spread="19.56" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="-10.3" spread="25.49" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="-21.1" spread="31.56" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="-22.5" spread="25.41" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12</title>
        <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
        <time_frame>Baseline and at week 12</time_frame>
        <population>FAS used for analysis, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection 0.5mg q4</title>
            <description>Participants received 0.5 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection 0.5mg q12</title>
            <description>Participants received 0.5 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection 2.0mg q4</title>
            <description>Participants received 2.0 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection 2.0mg q12</title>
            <description>Participants received 2.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O5">
            <title>Aflibercept Injection 4.0mg q12</title>
            <description>Participants received 4.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12</title>
          <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
          <population>FAS used for analysis, LOCF</population>
          <units>letters read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="9.20" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="3.8" spread="11.55" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="8.3" spread="10.14" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="5.2" spread="8.46" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="2.6" spread="8.72" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="5.7" spread="9.87" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12</title>
        <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
        <time_frame>At Week 12</time_frame>
        <population>FAS used for analysis, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection 0.5mg q4</title>
            <description>Participants received 0.5 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection 0.5mg q12</title>
            <description>Participants received 0.5 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection 2.0mg q4</title>
            <description>Participants received 2.0 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection 2.0mg q12</title>
            <description>Participants received 2.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O5">
            <title>Aflibercept Injection 4.0mg q12</title>
            <description>Participants received 4.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12</title>
          <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
          <population>FAS used for analysis, LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="21.9" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="25.8" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="16.1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="9.7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="18.5" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Change of CR/LT From Baseline at Week 16</title>
        <description>CR/LT measured in micrometers (µm); lower individual values represent better outcomes</description>
        <time_frame>Baseline and at Week 16</time_frame>
        <population>FAS used for analysis, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection 0.5mg q4</title>
            <description>Participants received 0.5 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection 0.5mg q12</title>
            <description>Participants received 0.5 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection 2.0mg q4</title>
            <description>Participants received 2.0mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection 2.0mg q12</title>
            <description>Participants received 2.0mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O5">
            <title>Aflibercept Injection 4.0mg q12</title>
            <description>Participants received 4.0mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of CR/LT From Baseline at Week 16</title>
          <description>CR/LT measured in micrometers (µm); lower individual values represent better outcomes</description>
          <population>FAS used for analysis, LOCF</population>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-163.3" spread="108.13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="-139.6" spread="126.41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="-182.7" spread="146.75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="-107.4" spread="112.22" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="-208.6" spread="202.07" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="-160.2" spread="145.34" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Change in BCVA as Measured by ETDRS From Baseline at Week 16</title>
        <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
        <time_frame>Baseline and at Week 16</time_frame>
        <population>FAS used for analysis, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept Injection 0.5mg q4</title>
            <description>Participants received 0.5 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection 0.5mg q12</title>
            <description>Participants received 0.5 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection 2.0mg q4</title>
            <description>Participants received 2.0 mg of aflibercept injection at 4 week intervals through Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection 2.0mg q12</title>
            <description>Participants received 2.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O5">
            <title>Aflibercept Injection 4.0mg q12</title>
            <description>Participants received 4.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
          </group>
          <group group_id="O6">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in BCVA as Measured by ETDRS From Baseline at Week 16</title>
          <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning</description>
          <population>FAS used for analysis, LOCF</population>
          <units>letters read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="9.92" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.6" spread="12.24" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="10.0" spread="9.76" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="4.3" spread="10.01" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="3.9" spread="9.92" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="6.6" spread="10.60" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) considered related to study treatment were followed until resolution or until the event was considered chronic or stable.</time_frame>
      <desc>Safety was assessed through reported AEs, clinical laboratory test results, vital signs, and ophthalmic examinations</desc>
      <group_list>
        <group group_id="E1">
          <title>Aflibercept Injection 0.5mg q4</title>
          <description>Participants received 0.5 mg of aflibercept injection at 4 week intervals through Week 12.</description>
        </group>
        <group group_id="E2">
          <title>Aflibercept Injection 0.5mg q12</title>
          <description>Participants received 0.5 mg of aflibercept injection at 12 week intervals through Week 12.</description>
        </group>
        <group group_id="E3">
          <title>Aflibercept Injection 2.0mg q4</title>
          <description>Participants received 2.0 mg of aflibercept injection at 4 week intervals through Week 12.</description>
        </group>
        <group group_id="E4">
          <title>Aflibercept Injection 2.0mg q12</title>
          <description>Participants received 2.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
        </group>
        <group group_id="E5">
          <title>Aflibercept Injection 4.0mg q12</title>
          <description>Participants received 4.0 mg of aflibercept injection at 12 week intervals through Week 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11"/>
                <counts group_id="E2" subjects_affected="5"/>
                <counts group_id="E3" subjects_affected="10"/>
                <counts group_id="E4" subjects_affected="7"/>
                <counts group_id="E5" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>UVEITIS</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSKINESIA OESOPHAGEAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SYNOVIAL RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTRAOCULAR PRESSURE INCREASED</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BRAIN NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>COORDINATION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SPINAL CORD DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>STRESS INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>PILONIDAL SINUS REPAIR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26"/>
                <counts group_id="E2" subjects_affected="25"/>
                <counts group_id="E3" subjects_affected="27"/>
                <counts group_id="E4" subjects_affected="22"/>
                <counts group_id="E5" subjects_affected="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CATARACT NUCLEAR</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CATARACT SUBCAPSULAR</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CHOROIDAL NEOVASCULARISATION</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DETACHMENT OF RETINAL PIGMENT EPITHELIUM</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>REFRACTION DISORDER</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RETINAL OEDEMA</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RETINAL PIGMENT EPITHELIOPATHY</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VITREOUS DETACHMENT</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VITREOUS FLOATERS</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>EYE INFLAMMATION</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>EYE IRRITATION</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY SENSATION IN EYES</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>LACRIMATION DECREASED</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MACULAR DEGENERATION</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>MACULOPATHY</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PHOTOPSIA</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PUNCTATE KERATITIS</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RETINAL DEPIGMENTATION</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SUBRETINAL FIBROSIS</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VISUAL DISTURBANCE</sub_title>
                <description>Study Eye</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>RHINOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>JOINT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INTRAOCULAR PRESSURE INCREASED</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DEMENTIA ALZHEIMER'S TYPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SINUS HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After completion of the trial, the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review; provided that the sponsor can remove confidential or proprietary information from such communications. The sponsor cannot require other changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a phase 2 study with small numbers of patients per group limiting the conclusions that can be drawn from the resulting data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trials Administrator</name_or_title>
      <organization>Regeneron Pharmaceuticals, Inc.</organization>
      <email>clinicaltrials@regeneron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

